The Britain-based international niche pharmaceutical business AMCo has opened an office in Dubai, UAE, to make more of its medicines available to doctors, hospitals and healthcare professionals in the Middle East.

Dubai becomes the hub for AMCo’s expansion into the region and North Africa including Saudi Arabia and Algeria, a statement said.
 
AMCo already has distributors in the region but believes an office closer to the countries in which it works will give patients better access to a wider selection of its medicines.

AMCo’s chief commercial officer Steve Higgins said: “We have such a wide product range, from treatments for patients with thyroid problems, through to the eye disease conjunctivitis which is common in the Middle East. We are in a better position to make these available in the region if we are based there.

“We will be closer to the people we want to help and to the doctors, nurses and pharmacists who are looking for cost-effective ways of treating patients.

“Dubai is an excellent location with strong transport links and communications across the region.”

“The new office was officially opened by AMCo CEO John Beighton in the presence of a number of AMCo’s long-standing regional partners”.

AMCo operates in 112 countries and has recently expanded its product range to include the medicine, Fucithalmic which treats conjunctivitis. 30 per cent of worldwide sales of the treatment are in the Middle East. If untreated, the disease can cause blindness in severe cases.

The Dubai office will be headed up buy AMCo’s Middle East and North Africa general manager Werner Rooseboom. - TradeArabia News Service